Close Menu

Editor's Pick

The company hopes to launch its first clinical cancer test within the next year, after spending the last several years conducting validation studies.

The firm's CEO Kevin Ness said confirmation of MAD7's editing activity in human HEK293T cells shows the potential for Inscripta's technology.

Organizers of a data analysis challenge remain hopeful that a recent update to the Connectivity Map resource will lead to breakthroughs in DILI detection by next year.

The study, which coupled FAIMS to an Orbitrap mass spec, indicates the technology could streamline proteomics experiments without sacrificing depth of analysis.

The researchers developed a protocol for dengue and chikungunya virus detection, which they plan to continue to test for outbreak monitoring and diagnostics.

DeCode's new offering adds to an ongoing controversy over whether people in the island country have a right to know if they are at increased risk for disease.

HHS may already be administering DNA testing to migrant families, but the agency has provided little information about how testing is being implemented.

Researchers at Columbia University and CHOP believe they can shorten time to diagnosis and improve yield by extracting phenotypic data from EHRs for genomic labs.

The company plans to use the new funding to grow its suite of genomics applications to more than 50 in 2018.

The company outlined its plans to launch a kidney transplant rejection test that is based on cell-free DNA in 2019 and described its progress in breast cancer research.

Pages

The Wall Street Journal reports on the struggle to meet the demand for rapid COVID-19 testing.

The Newsroom reports New Zealand is using genomics to trace the origins of its new coronavirus outbreak.

In Nature this week: researchers in Canada sequence the genome of the black mustard plant Brassica nigra, and more.

According to Bloomberg, Moderna has a $1.5 billion vaccine deal with the US to provide 100 million doses.